OBJECTIVE: The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed. The aim of this study was to examine type I IFNs as regulators of the inflammasome. METHODS: SLE patients fulfilled ≥4 American College of Rheumatology criteria and were recruited from the University of Michigan Lupus Cohort. Primary monocytes were isolated from SLE patients or healthy controls by negative selection, treated with inflammasome activators in the presence or absence of IFNα, and IL-1β secretion was measured by enzyme-linked immunosorbent assay. Expression levels of IFN and inflammasome-related molecules were assessed by real-time polymerase chain reaction and Western blotting. IFN regulatory factor 1 (IRF-1) expression was specifically down-regulated by small interfering RNA (siRNA) transfection and a chemical inhibitor. RESULTS: Monocytes from patients with SLE exhibited increased expression and enhanced activation of the inflammasome by ATP when compared with control monocytes. Expression of inflammasome and IFN-regulated genes was significantly correlated in monocytes from SLE patients but not in control monocytes. Inflammasome activity was increased after prolonged exposure to IFNα. Reduction of IRF-1 expression via siRNA blocked caspase 1 up-regulation after treatment with IFNα. Importantly, hyperactivity of the inflammasome in the monocytes of SLE patients was significantly reduced after knockdown or inhibition of IRF-1. CONCLUSION: Prolonged type I IFN exposure, as seen in SLE patients, primes monocytes for robust inflammasome activation in an IRF-1-dependent manner. IRF-1 inhibition may serve as a novel target for treatment of SLE-associated inflammation and organ damage.
OBJECTIVE: The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed. The aim of this study was to examine type I IFNs as regulators of the inflammasome. METHODS:SLEpatients fulfilled ≥4 American College of Rheumatology criteria and were recruited from the University of Michigan Lupus Cohort. Primary monocytes were isolated from SLEpatients or healthy controls by negative selection, treated with inflammasome activators in the presence or absence of IFNα, and IL-1β secretion was measured by enzyme-linked immunosorbent assay. Expression levels of IFN and inflammasome-related molecules were assessed by real-time polymerase chain reaction and Western blotting. IFN regulatory factor 1 (IRF-1) expression was specifically down-regulated by small interfering RNA (siRNA) transfection and a chemical inhibitor. RESULTS: Monocytes from patients with SLE exhibited increased expression and enhanced activation of the inflammasome by ATP when compared with control monocytes. Expression of inflammasome and IFN-regulated genes was significantly correlated in monocytes from SLEpatients but not in control monocytes. Inflammasome activity was increased after prolonged exposure to IFNα. Reduction of IRF-1 expression via siRNA blocked caspase 1 up-regulation after treatment with IFNα. Importantly, hyperactivity of the inflammasome in the monocytes of SLEpatients was significantly reduced after knockdown or inhibition of IRF-1. CONCLUSION: Prolonged type I IFN exposure, as seen in SLEpatients, primes monocytes for robust inflammasome activation in an IRF-1-dependent manner. IRF-1 inhibition may serve as a novel target for treatment of SLE-associated inflammation and organ damage.
Authors: Kyriakos A Kirou; Christina Lee; Sandhya George; Kyriakos Louca; Ioannis G Papagiannis; Margaret G E Peterson; Ngoc Ly; Robert N Woodward; Kirk E Fry; Anna Yin-Har Lau; James G Prentice; Jay G Wohlgemuth; Mary K Crow Journal: Arthritis Rheum Date: 2004-12
Authors: Stephan Meller; Franziska Winterberg; Michel Gilliet; Anja Müller; Ingrida Lauceviciute; Juliane Rieker; Norbert J Neumann; Robert Kubitza; Michael Gombert; Erich Bünemann; Ulrike Wiesner; Petra Franken-Kunkel; Holger Kanzler; Marie-Caroline Dieu-Nosjean; Ali Amara; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik; Bernhard Homey Journal: Arthritis Rheum Date: 2005-05
Authors: A E Karlsen; D Pavlovic; K Nielsen; J Jensen; H U Andersen; F Pociot; T Mandrup-Poulsen; D L Eizirik; J Nerup Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Christopher M Reilly; Selen Olgun; David Goodwin; Robert M Gogal; Arben Santo; Jason W Romesburg; S Ansar Ahmed; Gary S Gilkeson Journal: Eur J Immunol Date: 2006-05 Impact factor: 5.532
Authors: Johann E Gudjonsson; J Michelle Kahlenberg; Mrinal K Sarkar; Grace A Hile; Lam C Tsoi; Xianying Xing; Jianhua Liu; Yun Liang; Celine C Berthier; William R Swindell; Matthew T Patrick; Shuai Shao; Pei-Suen Tsou; Ranjitha Uppala; Maria A Beamer; Anshika Srivastava; Stephanie L Bielas; Paul W Harms; Spiro Getsios; James T Elder; John J Voorhees Journal: Ann Rheum Dis Date: 2018-07-18 Impact factor: 19.103
Authors: Allison C Billi; Mehrnaz Gharaee-Kermani; Joseph Fullmer; Lam C Tsoi; Brett D Hill; Dennis Gruszka; Jessica Ludwig; Xianying Xing; Shannon Estadt; Sonya J Wolf; Syed Monem Rizvi; Celine C Berthier; Jeffrey B Hodgin; Maria A Beamer; Mrinal K Sarkar; Yun Liang; Ranjitha Uppala; Shuai Shao; Chang Zeng; Paul W Harms; Monique E Verhaegen; John J Voorhees; Fei Wen; Nicole L Ward; Andrzej A Dlugosz; J Michelle Kahlenberg; Johann E Gudjonsson Journal: JCI Insight Date: 2019-04-18
Authors: Allison C Billi; Feiyang Ma; Olesya Plazyo; Mehrnaz Gharaee-Kermani; Rachael Wasikowski; Grace A Hile; Xianying Xing; Christine M Yee; Syed M Rizvi; Mitra P Maz; Celine C Berthier; Fei Wen; Lam C Tsoi; Matteo Pellegrini; Robert L Modlin; Johann E Gudjonsson; J Michelle Kahlenberg Journal: Sci Transl Med Date: 2022-04-27 Impact factor: 19.319
Authors: Min Sun Shin; Youna Kang; Elizabeth R Wahl; Hong-Jai Park; Rossitza Lazova; Lin Leng; Mark Mamula; Smita Krishnaswamy; Richard Bucala; Insoo Kang Journal: Arthritis Rheumatol Date: 2018-12-04 Impact factor: 10.995